Literature DB >> 35475906

[Role of human papillomavirus (HPV) in the development of skin cancer].

Daniel Hasche1, Baki Akgül2.   

Abstract

The incidence of nonmelanoma skin cancer, the most common cancer in humans, continues to rise. The development of precancerous actinic keratoses and cutaneous squamous cell carcinoma (cSCC) is associated with infection with human papillomavirus (HPV) of genus beta (betaHPV). Persistent betaHPV infections in immunocompetent individuals are generally very well controlled by the immune system and largely asymptomatic. However, immunosuppression results in high levels of betaHPV in the skin and consequently increased viral oncoprotein activity, which in turn leads to a significantly increased risk for skin cancer. However, even in immunocompetent individuals, the risk of cSCC increases with age as a result of accumulated UV-induced DNA damage in the skin. In these patients, the mechanism of betaHPV-dependent carcinogenesis seems to be different from that observed in immunocompromised patients. The underlying mechanism of oncogenesis in immunocompetent patients is currently less well understood. This review summarizes the current research data, which provide compelling evidence that cutaneous papillomaviruses, particularly in interaction with UV light, promote skin carcinogenesis via a "hit-and-run" mechanism by enhancing the genotoxic effects of UV light in the initial phases of this multistep process. Furthermore, an overview of novel vaccination strategies against papillomaviruses that are currently tested in clinical trials is provided, which could significantly improve the treatment options for high-risk patients in the future.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Animal models; Betapapillomaviruses; Immunosuppression; Squamous cell carcinoma; UV light

Mesh:

Year:  2022        PMID: 35475906     DOI: 10.1007/s00105-022-04990-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  5 in total

1.  Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.

Authors:  Somayeh Pouyanfard; Gloria Spagnoli; Lorenzo Bulli; Kathrin Balz; Fan Yang; Caroline Odenwald; Hanna Seitz; Filipe C Mariz; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

2.  Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus.

Authors:  K J Purdie; C J Sexton; C M Proby; M T Glover; A T Williams; J N Stables; I M Leigh
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

3.  Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.

Authors:  Daniel Hasche; Melinda Ahmels; Ilona Braspenning-Wesch; Sonja Stephan; Rui Cao; Gabriele Schmidt; Martin Müller; Frank Rösl
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

4.  Expression of different L1 isoforms of Mastomys natalensis papillomavirus as mechanism to circumvent adaptive immunity.

Authors:  Sabrina E Vinzón; Frank Rösl; Daniel Hasche; Yingying Fu; Rui Cao; Miriam Schäfer; Sonja Stephan; Ilona Braspenning-Wesch; Laura Schmitt; Ralf Bischoff; Martin Müller; Kai Schäfer
Journal:  Elife       Date:  2020-08-04       Impact factor: 8.140

Review 5.  RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.

Authors:  Bettina Huber; Joshua Weiyuan Wang; Richard B S Roden; Reinhard Kirnbauer
Journal:  J Clin Med       Date:  2021-03-03       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.